ZA975077B - Modulation of LC132 (opioid-like) receptor function. - Google Patents
Modulation of LC132 (opioid-like) receptor function.Info
- Publication number
- ZA975077B ZA975077B ZA9705077A ZA975077A ZA975077B ZA 975077 B ZA975077 B ZA 975077B ZA 9705077 A ZA9705077 A ZA 9705077A ZA 975077 A ZA975077 A ZA 975077A ZA 975077 B ZA975077 B ZA 975077B
- Authority
- ZA
- South Africa
- Prior art keywords
- opioid
- modulation
- receptor function
- receptor
- function
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96109462 | 1996-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA975077B true ZA975077B (en) | 1997-12-15 |
Family
ID=8222893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9705077A ZA975077B (en) | 1996-06-13 | 1997-06-09 | Modulation of LC132 (opioid-like) receptor function. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6326156B1 (xx) |
| JP (1) | JP3212537B2 (xx) |
| KR (1) | KR100247670B1 (xx) |
| CN (1) | CN1184254A (xx) |
| AR (1) | AR007548A1 (xx) |
| AU (1) | AU719519B2 (xx) |
| BR (1) | BR9703546A (xx) |
| CA (1) | CA2206192A1 (xx) |
| CZ (1) | CZ179597A3 (xx) |
| HU (1) | HUP9701032A3 (xx) |
| IL (1) | IL121017A0 (xx) |
| MX (1) | MX9704352A (xx) |
| NO (1) | NO972707L (xx) |
| NZ (1) | NZ328033A (xx) |
| PL (1) | PL320527A1 (xx) |
| TR (1) | TR199700482A2 (xx) |
| ZA (1) | ZA975077B (xx) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA80841C2 (en) * | 2002-10-07 | 2007-11-12 | Univ California | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) |
| WO2008030752A2 (en) * | 2006-09-07 | 2008-03-13 | N.V. Organon | Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| EP2096915A1 (en) * | 2006-11-20 | 2009-09-09 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| AU2009233711B2 (en) | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| CA2757679A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| US8927551B2 (en) * | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US9149465B2 (en) * | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| WO2011097233A1 (en) * | 2010-02-03 | 2011-08-11 | Infinity Pharmaceuticals, Inc. | Fatty acid amide hydrolase inhibitors |
| JP5981429B2 (ja) | 2010-07-28 | 2016-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 末梢に制限されたｆａａｈ阻害剤 |
| JP6092870B2 (ja) | 2011-08-19 | 2017-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | メタ置換ビフェニル末梢に限局されたｆａａｈ阻害剤 |
| US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| EP3988540A1 (en) | 2014-04-07 | 2022-04-27 | The Regents of the University of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
| CN114796446B (zh) * | 2021-01-22 | 2024-08-30 | 宁夏杞肽科技有限公司 | 孤啡肽治疗氯胺酮成瘾的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| DE3718317A1 (de) | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| EP0612845A3 (en) | 1993-02-26 | 1994-09-21 | American Cyanamid Co | Purified opioid receptor. |
| US6096513A (en) | 1993-05-20 | 2000-08-01 | Arch Development Corporation | Polynucleotides encoding KAPPA opiod receptors |
| US5658783A (en) * | 1993-11-08 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization | Mammalian methadone-specific opioid receptor gene and uses |
| US5476933A (en) * | 1994-11-16 | 1995-12-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Azepine synthesis via a diels-alder reaction |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| EP1241259A1 (en) | 1995-08-15 | 2002-09-18 | Universite Libre De Bruxelles | Peptide having pronociceptive properties |
-
1997
- 1997-05-27 CA CA002206192A patent/CA2206192A1/en not_active Abandoned
- 1997-06-03 US US08/868,355 patent/US6326156B1/en not_active Expired - Fee Related
- 1997-06-06 IL IL12101797A patent/IL121017A0/xx unknown
- 1997-06-06 NZ NZ328033A patent/NZ328033A/en unknown
- 1997-06-09 TR TR97/00482A patent/TR199700482A2/xx unknown
- 1997-06-09 ZA ZA9705077A patent/ZA975077B/xx unknown
- 1997-06-09 JP JP15117397A patent/JP3212537B2/ja not_active Expired - Fee Related
- 1997-06-11 CZ CZ971795A patent/CZ179597A3/cs unknown
- 1997-06-11 HU HU9701032A patent/HUP9701032A3/hu unknown
- 1997-06-11 AR ARP970102532A patent/AR007548A1/es unknown
- 1997-06-12 NO NO972707A patent/NO972707L/no not_active Application Discontinuation
- 1997-06-12 AU AU24853/97A patent/AU719519B2/en not_active Ceased
- 1997-06-12 KR KR1019970024220A patent/KR100247670B1/ko not_active IP Right Cessation
- 1997-06-12 MX MX9704352A patent/MX9704352A/es unknown
- 1997-06-12 PL PL97320527A patent/PL320527A1/xx unknown
- 1997-06-12 CN CN97113212A patent/CN1184254A/zh active Pending
- 1997-06-13 BR BR9703546A patent/BR9703546A/pt active Search and Examination
-
2001
- 2001-08-14 US US09/929,986 patent/US20020082213A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO972707L (no) | 1997-12-15 |
| HU9701032D0 (en) | 1997-07-28 |
| US6326156B1 (en) | 2001-12-04 |
| US20020082213A1 (en) | 2002-06-27 |
| PL320527A1 (en) | 1997-12-22 |
| HUP9701032A3 (en) | 2000-04-28 |
| MX9704352A (es) | 1997-12-31 |
| NZ328033A (en) | 1998-11-25 |
| AR007548A1 (es) | 1999-11-10 |
| AU2485397A (en) | 1997-12-18 |
| CZ179597A3 (cs) | 1998-03-18 |
| BR9703546A (pt) | 1998-09-29 |
| JP3212537B2 (ja) | 2001-09-25 |
| TR199700482A2 (xx) | 1998-01-21 |
| KR100247670B1 (ko) | 2000-06-01 |
| IL121017A0 (en) | 1997-11-20 |
| NO972707D0 (no) | 1997-06-12 |
| CN1184254A (zh) | 1998-06-10 |
| CA2206192A1 (en) | 1997-12-13 |
| HUP9701032A2 (hu) | 1998-08-28 |
| AU719519B2 (en) | 2000-05-11 |
| KR980003586A (ko) | 1998-03-30 |
| JPH1068724A (ja) | 1998-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL120027A0 (en) | Carrier | |
| EP0902643A4 (en) | ELECTROENCEPHALOGRAPHY-BASED ACTIVATION SYSTEM | |
| AU3060097A (en) | Java printer | |
| AU2237297A (en) | Harness | |
| ZA978889B (en) | New combination of steroids. | |
| ZA975077B (en) | Modulation of LC132 (opioid-like) receptor function. | |
| GB2321808B (en) | Single sideband modulators | |
| AU3900497A (en) | Latching system | |
| ZA971997B (en) | Resolution of threo-methylphenidate. | |
| GB9619724D0 (en) | Catalyst | |
| GB9626130D0 (en) | Improved doctor assembly | |
| AUPO039696A0 (en) | Improved anchoring system | |
| ZA9710860B (en) | Adhesives. | |
| AU6955498A (en) | Rearpoint securement system | |
| ZA978475B (en) | Sulphide containing peptides. | |
| AU133050S (en) | Carrier | |
| GB2320149B (en) | Modulators | |
| AU3019197A (en) | Improved anchoring system | |
| CA79530S (en) | Carrier | |
| GB9608274D0 (en) | Multicarrier modulation | |
| ZA977131B (en) | Stirring member. | |
| GB9611953D0 (en) | Discrete multi tone modulation systems | |
| ZA977691B (en) | Carrier. | |
| TW348880U (en) | Note modulation apparatus | |
| GB9606707D0 (en) | Phospatase modulator |